References
- Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555.
- Rehermann B. Pathogenesis of chronic viral hepatitis: Differential roles of T cells and NK cells. Nat Med. 2013;19(7):859–868. Vol.
- Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol. 2007;46(1):160–170. Vol.
- Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244.e3.
- Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309. Vol.
- Mozessohn L, Chan KKW, Feld JJ, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a Meta-analysis. J Viral Hepat. 2015;22(10):842–849.
- Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Metaanalysis and examination of FDA safety reports. Ann Oncol. 2011;22(5):1170–1180.
- Reddy KR, Beavers KL, Hammond SP, et al. Erratum: American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–219.
- Seto WK, Chan TSY, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736–3743.
- Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991. Cancer. 1996;78(10):2210–2215.
- Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698–3715.
- Cliff ERS, Sasadeusz J, Visvanathan K, et al. Very late-onset hepatitis B reactivation following chemoimmunotherapy. Leuk Lymphoma. 2021;62:1–5.
- Matsue K, Kimura SI, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010;116(20):4769–4776.
- Dominguez N, Manzano ML, Muñoz R, et al. Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen. Leuk Lymphoma. 2015;56(4):1160–1163.
- Colucci M, Carsetti R, Cascioli S, et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. JASN. 2016;27(6):1811–1822.
- Thiel J, Rizzi M, Engesser M, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19(1):1–7
- Ysebaert L, Gross E, Kühlein E, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy. Leukemia. 2010;24(7):1310–1316.
- Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145–153.
- Griggio V, Perutelli F, Salvetti C, et al. Immune dysfunctions and Immune-Based therapeutic interventions in chronic lymphocytic leukemia. Front Immunol. 2020;11:1–26
- Solman IG, Blum LK, Hoh HY, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:1–11.